two new rare cannabinoids

Biotech company biosynthesizes two new rare Cannabinoids

Separating and CBD from THC is no laughing matter, in fact, it takes nothing short of a laboratory to completely extract and refine cannabis into CBD.

The only other way to separate it, short of growing a CBD strong and THC weak strain of cannabis. Would be to produce a synthetic version of it.

Synthetic cannabinoids

Which is precisely what a life sciences company named Biomedican has done.

They are drawing significant attention for the rapid progress it’s made in low-cost methods of biosynthesizing rare cannabinoids. By using a strain of yeast named Yarrowia lipolytica to extract pharmaceutical-grade cannabinoids that are chemically identical to those extracted from cannabis plants. More recently, the company said it had also biosynthesized THCV/THCVA,

synthetic cannabinoids

Potential medical use

Two other minor cannabinoids, which have the potential to treat a variety of conditions, including Alzheimer’s, diabetes, and osteoporosis. Biomedican announced it had successfully biosynthesized CBG and CBGA.

These two non-psychoactive cannabinoids have shown promise to have broad anti-inflammatory, antimicrobial, and antioxidant functions. Which seem to have great potential for the medical field and use in clinical arenas for animals and people. The known health benefits of the cannabinoid include counteracting pain and nausea, as well as slowing the growth of cancer cells.

new rare cannabinoids

Massively reducing cost

While making the process a whole lot cheaper. The company states it could produce a synthetically identical gram of CBG for just $1 while the current market price sits at $20

An impressive feat for life sciences, and a step toward better understanding what these cannabinoids can do for us, when separated from the psychoactive part of the compound.

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *

Click to Hide Advanced Floating Content
en_US
×